Tetanus-diphtheriaa-acellular pertussis–inactivated polio virus vaccination during pregnancy is safe and boosts ...

Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative ...

Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) ...

Dengue fever, caused by a flavivirus named DENV, is a major global health challenge, risking almost half of the world's ...

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven ...

CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expre ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, has received conditional approval from the European ...

The global oncolytic virus cancer therapy market is poised for exceptional growth, expanding from an estimated USD 36.87 million in 2025 to an impressive USD 386.89 million by 2035, marking a Compound ...

India's first dengue vaccine, expected to launch in 2026 after local trials; WHO-approved jab offers two-dose protection ...